长春西汀联合灯盏花素对急性脑梗死患者血清低氧诱导因子-1α、半胱氨酸蛋白酶3水平及NIHSS评分的影响
|
摘要
目的探讨长春西汀联合灯盏花素治疗急性脑梗死(ACI)的效果。方法选取我院93例ACI患者,按照随机数字表法将其分为对照组(46例)和观察组(47例),对照组给予长春西汀治疗,观察组给予长春西汀联合灯盏花素治疗。比较两组患者治疗前、后NIHSS评分、临床疗效、治疗前、后血清HIF-1α、caspase-3水平、不良反应发生情况及SF-36评分。结果治疗2周后,两组NIHSS评分均显著降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。观察组治疗总有效率为89.36%,显著高于对照组的67.39%,差异具有统计学意义(P<0.05)。治疗2周后,两组血清HIF-1α、caspase-3水平均显著降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗2周后,观察组患者SF-36评分显著高于对照组,差异具有统计学意义(P<0.05)。结论长春西汀联合灯盏花素治疗ACI疗效确切,有助于改善神经功能,降低患者血清HIF-1α、caspase-3水平,提高患者生活质量,且安全性高,值得推广应用。
Objective To investigate the effects of vinpocetine combined with breviscapine in the treatment of acute cerebral infarction(ACI). Methods Ninety-three patients with ACI in our hospital were divided into control group(46 cases)and observation group(47 cases) according to random number table method. The control group was treated with vinpocetine,while the observation group was treated with vinpocetine and breviscapine. The NIHSS scores before and after treatment,clinical efficacy, the levels of serum HIF-1α and caspase-3 before and after treatment, adverse reactions and SF-36 scores before and after treatment were compared between the two groups. Results After 2 weeks of treatment, the NIHSS scores of the two groups decreased significantly, and that in the observation group was lower than the control group, the difference was statistically significant(P <0.05). The total effective rate of treatment of the observation group was 89.36%, which was significantly higher than 67.39% of the control group, the difference was statistically significant(P <0.05). After 2 weeks of treatment, the serum levels of HIF-1α and caspase-3 in both groups decreased significantly, and those in the observation group were significantly lower than the control group, the differences were statistically significant(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). After 2 weeks of treatment,the SF-36 score in the observation group was significantly higher than that in the control group, and the difference was statistically significant(P<0.05). Conclusion Vinpocetine combined with breviscapine in the treatment of ACI has a definite curative effect, it is helpful to ameliorate nerve function, reduce the levels of serum HIF-1α and caspase-3, improve the quality of life of patients, and with a high safety, which is worth popularizing and applying.
Objective To investigate the effects of vinpocetine combined with breviscapine in the treatment of acute cerebral infarction(ACI). Methods Ninety-three patients with ACI in our hospital were divided into control group(46 cases)and observation group(47 cases) according to random number table method. The control group was treated with vinpocetine,while the observation group was treated with vinpocetine and breviscapine. The NIHSS scores before and after treatment,clinical efficacy, the levels of serum HIF-1α and caspase-3 before and after treatment, adverse reactions and SF-36 scores before and after treatment were compared between the two groups. Results After 2 weeks of treatment, the NIHSS scores of the two groups decreased significantly, and that in the observation group was lower than the control group, the difference was statistically significant(P <0.05). The total effective rate of treatment of the observation group was 89.36%, which was significantly higher than 67.39% of the control group, the difference was statistically significant(P <0.05). After 2 weeks of treatment, the serum levels of HIF-1α and caspase-3 in both groups decreased significantly, and those in the observation group were significantly lower than the control group, the differences were statistically significant(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). After 2 weeks of treatment,the SF-36 score in the observation group was significantly higher than that in the control group, and the difference was statistically significant(P<0.05). Conclusion Vinpocetine combined with breviscapine in the treatment of ACI has a definite curative effect, it is helpful to ameliorate nerve function, reduce the levels of serum HIF-1α and caspase-3, improve the quality of life of patients, and with a high safety, which is worth popularizing and applying.
引文
[1]HUANG Y,XIA Z,WEI W,et al.The impact of leucoaraiosis on neurological function recovery in elderly patients with acute cerebral infarction:clinical study involving 279 Chinese patients[J].J Int Med Res,2014,42(3):857-862.
[2]CAMERLINGO M,TUDOSE V,TOGNOZZI M,et al.Predictors of recanalisation in acute cerebral infarction from occlusion of the terminal internal carotid artery or of the middle cerebral artery mainstem treated with thrombolysis[J].Int J Neurosci,2014,124(3):199-203.
[3]张小房.灯盏花素联合银杏达莫注射液治疗缺血性脑梗死的疗效及协同作用分析[J].中国实用神经疾病杂志,2016,19(18):41-42.
[4]贾建平,陈生弟.神经病学[M].7版.北京:人民卫生出版社,2013:175-180.
[5]侯凌波,乔利军,郭建文.灯盏细辛注射液对血瘀型急性脑梗死患者血清VEGF、MMP-9、EPCs水平的影响[J].中成药,2015,37(11):2373-2378.
[6]吕二保.舍曲林治疗脑梗死后抑郁对患者生活质量及抑郁程度的影响[J].临床医学,2016,36(3):50-51.
[7]李季泓.银杏叶黄酮联合奥扎格雷钠对急性脑梗死患者血清HIF-1α、TNF-α及Caspase-3的影响[J].长春中医药大学学报,2016,32(1):91-94.
[8]马新建,卢连伟,高立玲.灯盏花素对急性缺血性脑血管病患者血清copeptin、NT-proBNP、HIF-1α及IMA影响研究[J].中国生化药物杂志,2015,35(7):119-121.
[2]CAMERLINGO M,TUDOSE V,TOGNOZZI M,et al.Predictors of recanalisation in acute cerebral infarction from occlusion of the terminal internal carotid artery or of the middle cerebral artery mainstem treated with thrombolysis[J].Int J Neurosci,2014,124(3):199-203.
[3]张小房.灯盏花素联合银杏达莫注射液治疗缺血性脑梗死的疗效及协同作用分析[J].中国实用神经疾病杂志,2016,19(18):41-42.
[4]贾建平,陈生弟.神经病学[M].7版.北京:人民卫生出版社,2013:175-180.
[5]侯凌波,乔利军,郭建文.灯盏细辛注射液对血瘀型急性脑梗死患者血清VEGF、MMP-9、EPCs水平的影响[J].中成药,2015,37(11):2373-2378.
[6]吕二保.舍曲林治疗脑梗死后抑郁对患者生活质量及抑郁程度的影响[J].临床医学,2016,36(3):50-51.
[7]李季泓.银杏叶黄酮联合奥扎格雷钠对急性脑梗死患者血清HIF-1α、TNF-α及Caspase-3的影响[J].长春中医药大学学报,2016,32(1):91-94.
[8]马新建,卢连伟,高立玲.灯盏花素对急性缺血性脑血管病患者血清copeptin、NT-proBNP、HIF-1α及IMA影响研究[J].中国生化药物杂志,2015,35(7):119-121.